Usefulness of QuantiFERON®-TB Gold test in psoriatic patients under treatment with tumour necrosis factor blockers

Bibliography

• Chiricozzi A, Zhang S, Dattola A, et al. New insights into the pathogenesis of cutaneous autoimmune disorders. J Biol Regul Homeost Agents 2012;26(2):165-70
   PubMed Web of Science ®Google Scholar
• Pathirana D, Nast A, Ormerod AD, et al. On the development of the European S3 guidelines on the systemic treatment of psoriasis vulgaris: structure and challenges. J Eur Acad Dermatol Venereol 2010;24(12):1458-67
   PubMed Web of Science ®Google Scholar
• Galván-Banqueri M, Marín Gil R, Santos Ramos B, Bautista Paloma FJ. Biological treatments for moderate-to-severe psoriasis: indirect comparison. J Clin Pharm Ther 2013;38(2):121-30
   PubMed Web of Science ®Google Scholar
• Saraceno R, Saggini A, Pietroleonardo L, Chimenti S. Infliximab in the treatment of plaque type psoriasis. Clin Cosmet Investig Dermatol 2009;2:27-37
   PubMedGoogle Scholar
• Papoutsaki M, Talamonti M, Giunta A, et al. The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab. Dermatology 2010;221:43-7
   PubMed Web of Science ®Google Scholar
• Harris J, Keane J. How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin Exp Immunol 2010;161(1):1-9
   PubMed Web of Science ®Google Scholar
• Saraceno R, Chimenti S. How to manage infections in the era of biologics? Dermatol Ther 2008;21(3):180-6
   PubMed Web of Science ®Google Scholar
• Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104
   PubMed Web of Science ®Google Scholar
• Sánchez-Moya AI, Dauden E. Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: report of a case series with 144 patients. J Eur Acad Dermatol Venereol 2011;25:730-3
   PubMed Web of Science ®Google Scholar
• Scrivo R, Sauzullo I, Mengoni F, et al. Mycobacterial interferon-gamma release variations during long term treatment with tumor necrosis factor blockers: lack of correlation with clinical out come. J Rheumatol 2013;40(2):157-65
   PubMed Web of Science ®Google Scholar
• British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005;60:800-5
   PubMed Web of Science ®Google Scholar
• Menzies D. Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med 1999;159:15-21
   PubMed Web of Science ®Google Scholar
• Sauzullo I, Mengoni F, Scrivo R, et al. Evaluation of QuantiFERON-TB Gold In-Tube in human immunodeficiency virus infection and in patient candidates for anti-tumour necrosis factor-alpha treatment. Int J Tuberc Lung Dis 2010;14(7):834-40
   PubMed Web of Science ®Google Scholar
• Chiu HY, Hsueh PR, Tsai TF. Clinical experience of QuantiFERON® -TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan. Br J Dermatol 2011;164:553-9
   PubMed Web of Science ®Google Scholar
• Doherty SD, Van Voorhees A, Lebwohl MG, et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol 2008;59(2):209-17
   PubMed Web of Science ®Google Scholar
• Laffitte E, Janssens JP, Roux-Lombard P, et al. Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test. Br J Dermatol 2009;161(4):797-800
   PubMed Web of Science ®Google Scholar
• Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007;146:340-54
   PubMed Web of Science ®Google Scholar
• Narasimhan P, Wood J, Macintyre CR, Mathai D. Risk factors for tuberculosis. Pulm Med 2013;2013:828939
   PubMedGoogle Scholar
• Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000;161(4 Pt 2):S221-47
   PubMed Web of Science ®Google Scholar
• Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010;36(5):1185-206
   PubMed Web of Science ®Google Scholar
• Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2006;2(11):602-10
   PubMedGoogle Scholar
• American Thoracic Society. Review, Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 2000;4:1-51
   Google Scholar
• Garcovich S, Ruggeri A, D'Agostino M, et al. Clinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-term anti-TNF-alpha treatment: a prospective, observational study. J Eur Acad Dermatol Venereol 2012;26(12):1572-6
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Masud S, Ramamurthi R, et al. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor monoclonal antibody (Infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol 2003;48:68-75
   PubMed Web of Science ®Google Scholar
• Higuchi K, Kawabe Y, Mitarai S, et al. Comparison of performance in two diagnostic methods for tuberculosis infection. Med Microbiol Immunol 2009;198:33-7
   PubMed Web of Science ®Google Scholar
• Hill PC, Brookes RH, Fox A, et al. Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection. PLoS Med 2007;4:e192
   PubMed Web of Science ®Google Scholar
• Ewer K, Millington KA, Deeks JJ, et al. Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am J Respir Crit Care Med 2006;174:831-9
   PubMed Web of Science ®Google Scholar
• Park JS, Lee JS, Kim MY, et al. Monthly follow-ups of interferon-gamma release assays among healthcare workers in contact with TB patients. Chest 2012;142(6):1461-8
   PubMed Web of Science ®Google Scholar
• Diluvio L, Romiti ML, Angelini F, et al. Infliximab therapy induces increased polyclonality of CD4+CD25+ regulatory T cells in psoriasis. Br J Dermatol 2010;162(4):895-7
   PubMed Web of Science ®Google Scholar
• ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002;50(2):206-11
   PubMed Web of Science ®Google Scholar